Human IL-17C Antibodies Bivalent Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting IL-17C are not effective for human therapy as they are either polyclonal or specific to mouse IL-17C, lacking reactivity with human IL-17C, and there is a need for methods and compositions that can alter IL-17C-mediated signaling in humans to treat inflammatory disorders and cancers.
Innovation Solution
Development of antibodies or antibody fragments that bivalently bind to human IL-17C homodimers, forming stable complexes and blocking IL-17C's interaction with its receptor, thereby inhibiting IL-17C-mediated signaling, specifically targeting the PVLRPEEVL epitope on human IL-17C.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If polyclonal sera or monoclonal antibodies derived from immunized mice are used, then research tool availability is improved, but human therapeutic applicability deteriorates
Solution Approach 1:
The patent changes the species origin parameter of the antibody from mouse to human, creating humanized or fully human antibodies that maintain binding capability while enabling human therapeutic use. This parameter change resolves the contradiction by making the antibody suitable for human therapy while preserving its research and therapeutic utility.
2Reliability
If mouse-specific antibodies are used, then IL-17C binding capability is improved, but cross-reactivity with human IL-17C deteriorates
Solution Approach 1:
The patent changes the species origin parameter of the antibody from mouse to human, creating humanized or fully human antibodies that maintain binding capability while enabling human therapeutic use. This parameter change resolves the contradiction by making the antibody suitable for human therapy while preserving its research and therapeutic utility.
3Ease of operation
If conventional monovalent binding antibodies are used, then binding simplicity is improved, but antagonistic activity and signaling inhibition deteriorate
Solution Approach 1:
The patent merges two antigen-binding sites into a single antibody molecule that simultaneously binds both subunits of the IL-17C homodimer. This merging of binding functions creates bivalent antibodies that form stable 1:1 complexes with the homodimer, dramatically enhancing antagonistic activity and signaling inhibition compared to monovalent antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies or antibody fragments effectively inhibit IL-17C signaling, providing a promising therapeutic approach for inflammatory disorders and cancers by forming stable complexes with IL-17C homodimers and blocking receptor interaction, demonstrating outstanding antagonistic activity.
Implementation Method 1
the disclosed antibodies or antibody fragments bivalently bind to an IL-17C homodimer and form a complex consisting of said antibody or antibody fragment and one IL-17C homodimer
Implementation Method 2
The strong avidity effect as a result of the bivalent binding leads to the formation of very stable complexes between one IL-17C homodimer and such antibodies or antibody fragments
Implementation Method 3
the disclosed antibodies or antibody fragments inhibit interaction of IL-17C with its receptor and by the bivalent binding the disclosed antibodies or antibody fragments concurrently block both receptor interaction regions of the IL-17C homodimer
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that bivalently bind to homodimeric IL-17C.